633 related articles for article (PubMed ID: 30283029)
21. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
22. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
23. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
[TBL] [Abstract][Full Text] [Related]
24. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
25. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
26. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.
Altinay M; Karne H; Anand A
Psychopharmacol Bull; 2019 Feb; 49(1):8-16. PubMed ID: 30858635
[TBL] [Abstract][Full Text] [Related]
27. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
28. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
[TBL] [Abstract][Full Text] [Related]
29. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
30. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
31. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
32. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
[TBL] [Abstract][Full Text] [Related]
34. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
36. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
37. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Ibrahim L; Diazgranados N; Franco-Chaves J; Brutsche N; Henter ID; Kronstein P; Moaddel R; Wainer I; Luckenbaugh DA; Manji HK; Zarate CA
Neuropsychopharmacology; 2012 May; 37(6):1526-33. PubMed ID: 22298121
[TBL] [Abstract][Full Text] [Related]
38. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
[TBL] [Abstract][Full Text] [Related]
39. Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.
Chen MH; Wu HJ; Li CT; Lin WC; Tsai SJ; Hong CJ; Tu PC; Bai YM; Mao WC; Su TP
Hum Psychopharmacol; 2022 Mar; 37(2):e2820. PubMed ID: 34597436
[TBL] [Abstract][Full Text] [Related]
40. Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.
Colla M; Offenhammer B; Scheerer H; Kronenberg G; Vetter S; Mutschler J; Mikoteit T; Bankwitz A; Adank A; Schaekel L; Eicher C; Brühl AB; Seifritz E
J Psychiatr Res; 2024 May; 173():124-130. PubMed ID: 38522166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]